Total Funding
53
36
Total FundingPost-IPO Equity raised
Growth Score
-13 pts
Heat Score
-6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
68598
Gain Therapeutics is a biotech company developing pharmacological chaperones drugs designed to treat rare metabolic disorders.
- Lorenzo Leoni: Vice Chairman and Founder
Khalid Islam: Co-Founder and ChairmanPast Role: Gentium, CEO
About the Company
Gain Therapeutics is a developer of pharmacological chaperones drugs designed to treat rare metabolic disorders. The company's drugs utilize Minoryx Direct Enzyme Therapy to identify a new generation of uncomplicated adjuvants, enabling clients to help patients stabilize misfolding mutations and restore protein's enzymatic activity. It
targets lysosomal enzymes to develop innovative drugs for rare pediatric genetic disorders and selected CNS diseases with high unmet medical needs.
Established in 2017 and is headquartered in Bethesda, MD, USA.
